COA 看起来很完整，但质量保证部门仍无法证明测试及哪一批、哪符合规格、采用哪种方法。
一份有效的尿石素A级COA审核并非只是追求高定量值，而是严格检查该文件是否正确标识了正确的原料、批次、规格，报告了可解释的结果，并提供了足够的放行证据支持决策。如果缺少上述任何一项，该文件可能仅具有参考价值，以此作为放行依据。
本指南面向质量保证审核员、采购团队、配方师、进口商和合同制造商。它详细介绍了需要关注的领域、需要向供应商提出的问题，以及重点分析证书（COA）、批次批次分析证书、商业批次分析证书和独立实验室报告之间的区别。
质量原则保证：审查分析证书（COA）、规格说明和原材料批次之间的关系。缺少这些关联的结果并非完整的放行记录。
尿石素A分析证书能证明什么，又不能证明什么？
分析证书通常特定报告批次的特定结果测试。它可以用于支持来料审核、供应商资质认证、配方制定或批次放行。其价值取决于其主题范围和相关记录。
COA（分析证书）并不能自动证明库存在所有配方中均有效、在储存过程中保持不变、满足所有目标市场的要求或支持成品声明。此外，即使产品名称和含量测定结果看起来很相似，它也不会自动成为当前批量的记录。
COA 裁决证明
| 进攻决策 | COA可以做出贡献 | 可能需要更多证据 |
|---|---|---|
| 身份验证 | 报告的识别测试、产品代码和批号 | 当存在风险需要时，可进行独立验证或方法审查。 |
| 即将发布 | 实际结果与预定规格的对比 | 包装、残留记录仪和内部循环 |
| 供应商资质 | 方法、水资源、结果格式和发布实践 | 供应商历史记录、审计证据和定期确认 |
| 配方筛选 | 起始原料数据和物理描述 | 应用程序测试、矩阵和恢复成品格式数据 |
| 市场文件 | 文件范围内的批次和质量信息 | 目的地特定监管和标签审查 |
尿石实验室的质量框架描述了干扰可能要求的检测类型、相关物质、溶剂、元素和微生物信息。具体的释放范围仍取决于材料和项目的既定规范。
首先是文档标题和产品标识。
在解读任何结果之前，请先确认您所持有的文件。文件抬头应包含签发单位、产品名称、等级或材料代码、文件编号、签发日期以及修订或替换状态等信息。如果抬头信息不完整，则无法准确解读数值结果。
请将产品名称和代码与采购订单、供应商报价单、规格说明和包装标签进行核对。细微的格式差异可能无关紧要，但如果代码、等级或法律实体不同，则需要书面解释。
QA 应捕获的标头字段
| 场地 | 复习题 | 如有疑问，需跟进。 |
|---|---|---|
| 发行实体 | 这份分析证书是由哪家公司或实验室签发的？ | 确认其在测试和发布中的作用 |
| 产品名称 | 它是否与已批准的材料标识相符？ | 要求提供更正或核对后的描述 |
| 产品或等级代码 | 代码是否符合规范和订单要求？ | 检查代码是否已更改或指向其他等级 |
| 文件编号 | COA（分析证书）能否被检索和控制？ | 请求受控文件引用 |
| 发布日期和修订 | 该单据是否适用于此次发货？ | 询问发布时生效的版本是什么 |
| 页面控制 | 页码和总页数是否可见？ | 如果文件缺少页面，请索取完整文件。 |
供应商可以使用品牌模板、实验室报告或电子证书。格式的重要性远不及控制、完整性以及将文件与实物批次关联起来的能力。
确认批号、批次和包装标识
批号是分析证书 (COA) 的核心。它应与收到的容器上的标签以及装箱单、发票和抽样记录中的批次或批号标识符相符。如果供应商使用单独的生产编号、放行编号和包装编号，请询问它们之间的对应关系。
记录生产日期、抽样日期、测试日期、放行日期、复检或有效期信息（如有提供），以及所代表的容器数量或净含量。这些日期有助于质量保证部门判断文件描述的物料是否与实际收到的物料相符。
批次核对检查
- Photograph or transcribe the lot number from the outer package and inner label.
- Compare the lot with the COA, packing list, invoice and purchase order.
- Check whether the sample was taken from the same lot as the commercial shipment.
- Confirm that the number of containers or quantity on the COA matches the shipment scope.
- Ask whether the COA covers a single lot, a blend of lots or a continuous-production quantity.
- Record any relabelling, repacking or consolidation before deciding release status.
A sample COA may be valid for the sample lot and still be unsuitable for a different commercial lot. The document needs to state, or the supplier needs to confirm in writing, what quantity and lot it represents.
Read the specification reference before the result column
Every pass or fail statement has meaning only against a defined specification. Find the specification number, version, issue date or limit set referenced by the COA. Then retrieve that specification and compare the fields directly.
Do not assume that two documents with the same product name use the same limits. Assay basis, related-substance reporting, solvent panel, microbiological criteria, particle description and storage conditions can change between grades, markets or revisions.
Specification-to-COA map
| COA element | Specification question | QA conclusion |
|---|---|---|
| Test name | Does the COA include every required release field? | Missing fields are gaps, even when assay passes |
| Method | Does the method reference match the specification? | Method mismatch needs technical review |
| Limit | Is the reported acceptance criterion current? | Old limits cannot silently replace the approved version |
| Units | Are units and calculation basis identical? | Unit differences can change the meaning of a result |
| Result format | Is the field reported as numerical, qualitative or absent? | “Complies” may be insufficient for a critical field |
| Disposition | Does the final release statement cover the agreed panel? | Release status must reflect the complete specification |
For the U.S. dietary supplement context, 21 CFR 111.70 describes specifications for components and finished dietary supplements, including identity, purity, strength, composition and contamination limits. It is not a universal Urolithin A monograph. Buyers in other markets should use the requirements that apply to their product category and role.
Evaluate identity fields separately from assay
Assay is not identity. A main chromatographic peak with an expected area does not by itself establish that the material is the named compound. Identity may use a separate technique, a reference comparison, retention-time criteria or another defined approach.
Ask which identity test the supplier uses, what reference or comparison is applied, and how the result is recorded. If the COA says only “identified” or “passes,” review the underlying method summary when the risk or intended use requires more detail.
PubChem identifies Urolithin A as CID 5488186 with molecular formula C13H8O4 and molecular weight 228.20 in its public compound record. Public identifiers help QA check naming consistency, but they do not replace lot-specific identity testing.
Identity review questions
- Is the identity field tied to the same lot as the assay field?
- Does the method distinguish the target from related urolithin compounds or process residues?
- Is the reference standard identified and controlled?
- Are chromatograms, spectra or method summaries available when required by the quality agreement?
- Does the identity test apply to the received form, including any repacked or blended material?
Interpret assay, purity and related substances together
A reported assay value has no universal meaning outside its method and calculation basis. QA should record whether the result is reported on an as-is basis, dried basis, area-normalised basis or another basis. The document should state units and, where relevant, the reference standard and calculation approach.
Review related substances alongside the main assay. A high main-peak percentage may not describe individual impurities, unknown peaks or total related compounds if those fields are not included. The buyer’s specification should state what is named, what is unknown, which reporting threshold applies and how the total is calculated.
Assay result questions
| Field | What QA should look for | Why it changes interpretation |
|---|---|---|
| Reported value | Numerical result with unit and decimal precision | Rounding can hide proximity to a limit |
| Basis | As-is, dried, area normalised or other calculation basis | Different bases are not directly interchangeable |
| Method | Technique, detector, reference and method version | Method design affects selectivity and result meaning |
| Related peaks | Individual, unknown and total reporting fields | Main assay alone may not show the impurity profile |
| Reporting threshold | Limit below which a peak is not quantified or listed | “Not detected” and “below threshold” are different statements |
| Replicates | Whether the reported result is single, duplicate or averaged | Shows how much measurement variation was considered |
When a result is close to a limit, ask QA or the laboratory to review the method uncertainty, rounding convention and specification rule. Do not create a new acceptance margin by informal arithmetic.
Review physical and water-related fields for the intended use
Physical fields can determine whether a powder can be weighed, blended, transferred or dispersed in the buyer’s process. They may include appearance, colour description, particle-size information, bulk density, flow-related observations, moisture or loss on drying.
Each field needs a defined method or observation basis. “White powder” is a visual description, not a particle-size result. A mesh statement is not the same as a full particle distribution. Loss on drying is not identical to a water-specific method. QA should preserve those distinctions.
Physical-field review
| Field | Review point | Application consequence to investigate |
|---|---|---|
| Appearance | Defined description, sample condition and observation date | Colour or agglomeration may affect screening, but does not establish assay |
| Particle information | Method, sample preparation and reporting statistic | Can influence flow, segregation, wetting or dispersion |
| Moisture or loss on drying | Test name, conditions, units and limit | May affect handling, compression, storage or matrix behaviour |
| Bulk properties | Procedure, equipment and whether value is typical or lot-specific | May change fill, blend volume or transfer |
| pH or solubility note | Medium, temperature, concentration and method | Cannot be transferred to every formulation base |
Use the product’s current specification framework to identify which physical fields may matter to a project, then confirm the actual method and lot result on the COA or supporting file.
Check residual solvents, elemental impurities and microbiology
Quality panels should reflect the material route, intended use and applicable limits. A COA that lists “passes” without the panel, method or reporting units may be difficult for QA to defend during an audit or customer review.
For residual solvents, identify which solvents are included, which are not applicable to the process and whether the result is numerical or qualitative. For elemental impurities, check the individual elements, units, limits and method. For microbiology, review organisms, enumeration units, absence tests, sample quantity and incubation or method reference where required.
Contaminant-field questions
- Does the panel reflect the supplier’s stated process and the buyer’s intended use?
- Are the limits expressed in the same units as the buyer’s specification?
- Does “not detected” identify the reporting limit?
- Are individual results shown where the specification requires individual control?
- Was the sample taken from the same lot and under the same release process as the assay?
- Are subcontract laboratory reports linked to the COA and lot identifier?
Do not use a generic contaminant statement as proof that every possible hazard has been assessed. QA should map the panel to the material, process, market and risk assessment.
Verify sampling, laboratory and method traceability
A COA result is only as representative as the sample and method behind it. QA should be able to answer who selected the sample, from which containers, when it was tested, where the analysis occurred and how the result was approved.
The COA may not contain every laboratory record. In that case, the supplier should still provide the document references or controlled summaries required by the quality agreement. For critical materials, request enough detail to reconstruct the path from container to result.
Traceability fields beyond the COA page
| Record | QA question | Evidence to retain |
|---|---|---|
| Sampling plan | How many containers and which locations were sampled? | Sampling record or supplier statement |
| Laboratory identity | Which laboratory performed each test? | Internal lab name or subcontract report |
| Method version | Which controlled procedure was in force? | Method identifier and revision |
| Reference standard | Which standard supported identity or response? | Standard ID, lot or qualification reference |
| Data review | Who checked calculations and raw data? | Review or approval record when required |
| Release authority | Who authorised the final disposition? | Signature, electronic approval or controlled release field |
A supplier does not need to expose proprietary raw data during an initial enquiry. The buyer should, however, define which records are required for qualification, incoming release, investigation or customer audit.
Check dates, retest information and storage statements
Manufacturing, sampling, testing and release dates should form a plausible sequence. A release date before the final test date, an expired document or a retest statement without a defined condition should trigger a question.
Read the storage instruction together with the packaging information. A stability or retest statement is meaningful only under the stated container, temperature, humidity, light and time conditions. It does not automatically transfer to a repacked sample or a finished formula.
Date and storage review
- Manufacturing or batch date is visible and matches the supplier’s lot record.
- Sampling and testing dates are consistent with the release sequence.
- Release date follows completion of the required panel.
- Retest or expiry information has a defined basis and responsible issuer.
- Storage conditions match the package and shipping instructions.
- Any temperature excursion or repacking event is documented before release.
Compare representative, sample-lot and commercial-lot COAs
QA teams often receive a representative COA during supplier qualification, a sample-lot COA during formulation and a commercial-lot COA at receipt. These documents serve different decisions and should not be mixed.
COA type comparison
| COA type | What it supports | What it cannot establish alone |
|---|---|---|
| Representative COA | Early review of panel, format and reporting style | Current stock, sample identity or commercial-lot results |
| Sample-lot COA | Technical evaluation of the identified sample lot | Performance or release of a different commercial lot |
| Commercial-lot COA | Incoming review against the agreed purchase specification | Finished-product performance or universal market compliance |
| Third-party report | Independent result for the submitted sample and method scope | Replacement of the supplier’s complete batch-release file |
| Retest or stability report | Change under stated conditions and time points | Every lot or every package configuration |
Mark the COA type in the internal file name and review status. This prevents a representative document from being accidentally attached to a purchase order as if it were the current lot release.
Use the U.S. COA rules as a defined reference, not a global shortcut
In the U.S. dietary supplement context, 21 CFR 111.75 describes conditions under which a manufacturer may rely on a component supplier’s COA for certain specifications. The rule includes supplier qualification, confirmation of the reliability of supplier results, method and limit information, actual results, and periodic reconfirmation. It also addresses identity testing for dietary ingredients.
The section does not mean that a buyer in every country or product category can accept any supplier COA without review. It is a useful quality-system reference because it distinguishes receiving a certificate from establishing why the certificate is reliable for the intended decision.
For recordkeeping, 21 CFR 111.95 describes records that apply in the same U.S. dietary supplement framework. Buyers should still follow their own quality system, contract terms and destination-market obligations.
Handle a COA discrepancy with a controlled workflow
A discrepancy is not automatically a failed batch, but it should never disappear into an email thread. QA should classify the issue, preserve the original document, place the material under the appropriate status and ask the supplier for a traceable response.
COA discrepancy workflow
- Preserve: save the original file, package photographs, lot label and receipt record.
- Define: describe the exact conflict—lot number, unit, method, limit, result, date or signature.
- Contain: place the material on hold while the review is open, according to the buyer’s procedure.
- Ask: request a corrected document, explanation, method context or investigation reference.
- Compare: reconcile the answer against the specification, purchase order and physical material.
- Decide: release, conditionally accept, re-test, return or reject using an authorised disposition.
- Close: record root cause, corrective action and any supplier follow-up or change-control need.
Do not ask for a new COA that merely removes an inconvenient result. A corrected document should preserve the reason for correction and the approval trail.
Separate “pass” from “fit for the project”
A COA can show that a lot meets its agreed raw-material specification. It cannot by itself establish that the lot fits every capsule, powder, beverage or other finished format. Formulation teams still need matrix-specific recovery, compatibility, processing and stability work.
Likewise, a raw-material COA is not a finished-product release certificate. The finished product has its own composition, manufacturing record, tests and acceptance criteria. Keeping these decisions separate prevents a correct raw-material document from being overinterpreted.
Raw-material release versus formulation fit
| Question | COA answer | Separate project evidence |
|---|---|---|
| Is this the named material? | Identity field and lot result | Finished-product identity where required |
| Does the lot meet its specification? | Results compared with current limits | Finished-product specification and release testing |
| Will it blend or disperse? | Physical data may inform the screen | Application trial on the buyer’s equipment and base |
| Will the finished product remain stable? | Raw-material stability information | Finished formula and package study |
| Can a claim be used? | Usually no conclusion about claims | Evidence and regulatory review for the finished product |
Build a QA review checklist that another reviewer can repeat
A strong COA review leaves an audit trail that another qualified reviewer can follow without relying on the original reviewer’s memory. Use controlled statuses such as complete, incomplete, clarification requested, accepted with condition or rejected.
Repeatable QA checklist
- COA file is complete, legible and under document control.
- Issuing entity and product code match the approved supply chain.
- Lot, batch, package and quantity reconcile to the received material.
- Specification number and revision are current and retrievable.
- Identity field and method are appropriate for the material.
- Assay result includes units, basis, method and actual value.
- Related substances and reporting thresholds match the specification.
- Physical, moisture, solvent, elemental and microbiological fields match the agreed panel.
- Sampling, laboratory, method and release references are sufficient for the decision.
- Dates, storage, retest or expiry information are internally consistent.
- Any discrepancy has an owner, status and documented disposition.
- Raw-material release is not being used as finished-product or claim evidence.
The technical resources page can help organise a document request. For a lot-specific review, ask for the current COA, specification and document versions together rather than reviewing a single PDF in isolation.
Score COA quality by evidence strength, not document design
Some COAs are visually polished but technically thin. Others are plain but contain the fields QA needs. Use a simple evidence scorecard to keep design, branding and file length from replacing the actual review.
COA evidence scorecard
| Area | Strong evidence | Conditional evidence | Gap |
|---|---|---|---|
| Identity | Method, criterion and lot-linked result | Pass statement with method available on request | No identity basis |
| Assay | Value, unit, basis, method and result date | Value and method reference but limited calculation context | Headline purity only |
| Specification | Current number, version and limits | Supplier confirms current version separately | No specification link |
| Traceability | Lot, sample, laboratory and release records connect | Lot is clear but supporting records are pending | Generic or mismatched lot |
| Release | Authorised disposition and controlled signature | Electronic approval reference available | Undated or unsigned file |
Use the scorecard to prioritise follow-up. It is not a substitute for the buyer’s formal release procedure or risk assessment.
Frequently asked questions
What is the most important field on a Urolithin A COA?
No single field is sufficient. Lot identity, current specification, identity method, assay basis, actual results and release authority must connect. A high assay number cannot compensate for an untraceable lot or missing specification.
Is a COA with “passes” beside every test acceptable?
It depends on the buyer’s specification and quality system. For critical fields, QA may need actual numerical results, units, limits and method references rather than a general pass statement. Ask the supplier to define what the pass represents.
Can I use a representative COA to release a shipment?
Usually a representative COA supports preliminary qualification, not lot-specific incoming release. The buyer should request the commercial-lot COA or a documented release arrangement that matches the approved quality system.
Why does the assay basis matter?
An as-is result, dried-basis result and area-normalised result are calculated differently. Without the basis, two reported percentages may not be comparable and a limit decision may be wrong.
Should related substances appear on every Urolithin A COA?
The required panel depends on the agreed specification, process, product category and market. QA should confirm that the panel is appropriate and that the COA explains what is named, unknown, total and below the reporting threshold.
Does a third-party laboratory report replace a supplier COA?
Not automatically. A third-party report covers the sample, method and scope of that laboratory. The supplier COA belongs to the supplier’s release system. The buyer should connect both records to the same material and understand the purpose of each.
What should QA do when the COA and label disagree?
Place the issue into the buyer’s discrepancy process, preserve the original records and hold the material according to the quality system. Ask the supplier to reconcile the lot, product code, package and release file before an authorised disposition.
Does a passing COA prove a finished product will remain stable?
No. The COA describes the raw-material lot under its defined method and specification. Finished-product stability depends on the formula, process, package, storage conditions and matrix-specific analytical method.
Make every COA review produce a clear decision
The best COA review ends with a documented decision, not a folder full of PDFs. QA should be able to state which material and lot were reviewed, which specification and methods applied, which gaps remain, and who authorised the next action.
对于尿石素A的分析证书（COA），应从外到内阅读：文件控制、产品和批次标识、规格版本、方法、限度、实际结果、取样和实验室可追溯性、日期、放行权限和差异状态。这种顺序可以避免审核人员被主要检测结果分散注意力，从而发现最重要的漏洞。
请通过尿石素A采购简报索取当前规格、代表性批次或商业批次的COA及相关质量文件。如需就特定批次的质量保证进行讨论，请使用质量文件申请表，并注明目标市场、产品阶段以及贵公司质量体系要求的字段。
范围说明：本文是一个B2B原料质量框架。它不能取代侵犯已验证的方法、质量协议、来料检验程序、法规评估或成品放行体系。